Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 6;13:874056. doi: 10.3389/fimmu.2022.874056

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Liu, Wang, Sun, Jiang and Gong

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Correlation between LR.score and response to anti-PD-L1 immunotherapy. (A) Differences in LR.score between responders and non-responders in the IMvigor210 cohort. (B) The proportion of patients responding to immunotherapy in the high and low LR.score groups in the IMvigor210 cohort. (C) Prognostic differences between the high and low LR.score groups in the IMvigor210 cohort. (D) Prognostic differences between the high and low LR.score groups in early-stage patients in the IMvigor210 cohort. (E) Prognostic differences between the high and low LR.score groups in advanced patients in the IMvigor210 cohort. (F) LR.score differences between responders and non-responders in GSE78220. (G) The proportion of patients responding to immunotherapy in the high and low LR.score groups in GSE78220. (H) Prognostic differences between the high and low LR.score groups in GSE78220. ns p≥0.05; *p< 0.05; **p<0.01.